Skip to main content
SpringerLink
Log in

Guidelines can reduce the risk of clozapine-induced agranulocytosis

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mendelowitz AJ, Gerson SL, Alvir JMaJ, et al. Clozapine-induced agranulocytosis. Risk factors, monitoring and management. CNS Drugs 1995; 4(6): 412–21

    CAS  Google Scholar 

  2. Balon R, Berchov R. Hematological side effects of psychotropic drugs. Psychosomatics 1986; 27: 119–27

    Article  PubMed  CAS  Google Scholar 

  3. Jalenques I. Drug-resistant schizophrenia. Treatment options. CNS Drugs 1996; 5(1): 8–23

    CAS  Google Scholar 

  4. Antipsychotic selection depends on individual response and tolerability. Drug Ther Perspect 19 Jul 1993; 2(1): 8–11

    Article  Google Scholar 

  5. Clozapine: indications are defined by clinical not economic criteria. Drug Ther Perspect 22 Nov 1993; 2(10): 5–7

    Article  Google Scholar 

  6. Alvir JMaJ, Lieberman JA, Safferman AZ. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7

    Article  PubMed  CAS  Google Scholar 

  7. Alvir JMaJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55 (9 Suppl. b): 137–8

    Google Scholar 

  8. Alvir JMaJ, Lieberman JA, Safferman AZ. Do white-cell count spikes predict agranulocytosis in clozapine recipients. Psychopharmacol Bull 1995; 31: 311–4

    PubMed  CAS  Google Scholar 

  9. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945–8

    Article  PubMed  CAS  Google Scholar 

  10. Honigfeld G. Effects of the clozapine national registry system on the incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–56

    PubMed  CAS  Google Scholar 

  11. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 (9 Suppl. b): 139–42

    Google Scholar 

  12. Gerson SL. Clozapine: deciphering the risks [editorial]. N Engl J Med 1993: 204–5

  13. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991; 5: 21–33

    CAS  Google Scholar 

  14. Safferman AZ, Lieberman JA, Alvir JMaJ, et al. Rechallenge in clozapine-induced agranulocytosis [letter]. Lancet 1992; 340: 1097

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guidelines can reduce the risk of clozapine-induced agranulocytosis. Drugs Ther. Perspect 7, 10–13 (1996). https://doi.org/10.2165/00042310-199607090-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607090-00004

Search

Navigation